As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
17 Analysts have issued a SAGE Therapeutics, Inc. forecast:
17 Analysts have issued a SAGE Therapeutics, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 70 70 |
28%
28%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -302 -302 |
37%
37%
|
EBIT (Operating Income) EBIT | -303 -303 |
37%
37%
|
Net Profit | -301 -301 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Barry Greene |
Employees | 353 |
Founded | 2010 |
Website | www.sagerx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.